Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mary J. Bossard"'
Autor:
Mary J. Bossard
PEGylated protein conjugates submitted as therapeutic products qualify for Biologics License Applications as new chemical entities or new molecular entities. Even an improved version of an existing product must still undergo regulatory consideration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9fc1f91e6b0e99954057b62397b5bc7
https://doi.org/10.1016/b978-0-444-64081-9.00007-3
https://doi.org/10.1016/b978-0-444-64081-9.00007-3
Autor:
Amr S. Abu Lila, Rosalía Agusti, Sahar Awwad, Carsten Behrens, Mary J. Bossard, Gunda Brandenburg, Steve Brocchini, Jens Buchardt, Chris Caster, Victor R. de la Rosa, Rosa M. de Lederkremer, Celine Derunes, Nehal E. Elsadek, Elaine L. Ferguson, Marc A. Gauthier, M. Eugenia Giorgi, Kenneth Grabstein, Andrea A. Greschner, Antonella Grigoletto, Richard Hoogenboom, Tatsuhiro Ishida, Waliul Islam, Nandini V. Katre, Hanieh Khalili, Ralf Krähmer, Michael J. LaBarre, Frank Leenders, Gary Li, Kenneth W. Locke, Hiroshi Maeda, Daniel C. Maneval, Katia Maso, Mann Muhsin, Natalie Winblade Nairn, Steffen Nock, Gianfranco Pasut, Christina Picken, Sabine Poppenborg, Christoph Radcke, Sybille Sauter, Ondrej Sedlacek, Rose E. Sekulovich, Kurt D. Shanebeck, Jürgen Siekmann, Joana Stokniene, David W. Thomas, Curtis B. Thompson, Peter L. Turecek, Mathieu Varache, María J. Vicent, Aijun Wang, Julia Wittmann, Ahlem Zaghmi, Samuel Zalipsky, Mire Zloh, Linglong Zou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5499b541259ce8ea55013fa36b35449
https://doi.org/10.1016/b978-0-444-64081-9.01002-0
https://doi.org/10.1016/b978-0-444-64081-9.01002-0
Autor:
María J. Vicent, Mary J. Bossard
Regulatory authorities have approved several polyethylene glycol (PEG)–conjugated biological drugs and many more are currently in clinical trials. Biosimilars and follow-on versions of previously approved PEG conjugates are also gaining approval. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bec60cf5bdcb3f8796bffb076d6e2eae
https://doi.org/10.1016/b978-0-444-64081-9.00002-4
https://doi.org/10.1016/b978-0-444-64081-9.00002-4
Publikováno v:
Journal of Pharmaceutical Sciences. 105:460-475
Modification of biopharmaceutical molecules by covalent conjugation of polyethylene glycol (PEG) molecules is known to enhance pharmacologic and pharmaceutical properties of proteins and other large molecules and has been used successfully in 12 appr
Autor:
David G. Tew, Mark Alan Levy, Thaddeus A. Tomaszek, Thomas D. Meek, Daniel F. Veber, Stacie Halpert, Michael J. Huddleston, Steven A. Carr, Carl F. Ijames, Jacques Briand, Scott K. Thompson, Mary J. Bossard
Publikováno v:
Biochemistry. 38:15893-15902
The nature of the inhibition of thiol proteases by a new class of mechanism-based inhibitors, 1,5-diacylcarbohydrazides, is described. These potent, time-dependent, active-site spanning inhibitors include compounds that are selective for cathepsin K,
Autor:
Thomas Joseph Carr, Mary J. Bossard, Alison M. Badger, Thaddeus A. Tomaszek, Fred H. Drake, Mark Alan Levy, Lawrence Szewczuk, Scott K. Thompson, Ian E. James, Bartholomew J. Votta, Daniel F. Veber, Maxine Gowen, Janice R. Connor, R.A. Dodds, Bradbeer Jeremy N
Publikováno v:
Journal of Bone and Mineral Research. 12:1396-1406
We have shown previously that cathepsin K, a recently identified member of the papain superfamily of cysteine proteases, is expressed selectively in osteoclasts and is the predominant cysteine protease in these cells. Based upon its abundant cell typ
Autor:
Charles R. Hanning, Jeff Kurdyla, F. Drake, Bernard Y. Amegadzie, Mark Alan Levy, Thaddeus A. Tomaszek, Scott K. Thompson, Mary J. Bossard, M. Gowen, Dean E. McNulty, Christopher K. R. T. Jones
Publikováno v:
Journal of Biological Chemistry. 271:12517-12524
Human cathepsin K is a recently identified protein with high primary sequence homology to members of the papain cysteine protease superfamily including cathepsins S, L, and B and is selectively expressed in osteoclasts (Drake, F. H., Dodds, R., James
Autor:
Jürgen Siekmann, Friedrich Scheiflinger, Birgit K. Seyfried, Günter Allmaier, Peter Turecek, Mary J. Bossard, Martina Marchetti-Deschmann
Publikováno v:
Biotechnology journal. 7(5)
PEGylation is the most successful approach, to date, to prolong the in vivo survival of recombinant proteins. The conjugation of the polymer to glycoproteins results in challenging analysis, and furthermore, requires a wide variety of analytical tool
Autor:
Randall K. Johnson, M. Brandt, Mark Alan Levy, Mary J. Bossard, Derk J. Bergsma, George P. Livi, Wai-Kwong Eng
Publikováno v:
Biochemical Journal. 297:365-372
The binding of FK506 and rapamycin to their cytosolic receptor FKBP12 is an intermediate step in the paths leading to their potent immunosuppressive properties. One of the amino acids defining the hydrophobic binding cleft for the macrocycles is Tyr8
Autor:
Mary J. Bossard, Arnold J. Krog, Hwa-Kwo Yen, Karl F. Erhard, Arda Konialian-Beck, Elizabeth Ortiz, Hye-Ja Oh, Martin Brandt, Mark Alan Levy, Dennis A. Holt, Juan I. Luengo, Leonard W. Rozamus
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 4:315-320
A series of non-macrocyclic pipecolyl α-ketoamides were prepared and evaluated as FKBP cis-trans peptidyl-prolyl isomerase inhibitors. These compounds exhibited inhibition constants as low as 2 nM. Their design was based on a consideration of the co